Company Dossier · Health Care
Quest Diagnostics
- S&P 500
- Russell 1000
What Quest Diagnostics is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $11.6 billion, up 9.9% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $1.35 billion, up 11% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.55 billion, up 22% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.45 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $0.41 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 23, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
- Latest annual report (filed February 26, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $8.3 million on the open market.SEC Form 4
- 1,113 institutional managers reported a position at June 30, 2026 (+44 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 17 (13 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 1 — latest OSHA inspection, Nov 28, 2025 →
Company Posture
How Company Posture is measured →What Quest Diagnostics is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Expanding · Confident
Expanding ↔ Retrenching
Expanding
- Capital spending77th pct
- Debt raised38th pct
- Buybacks vs capex—
- Hiring filings78th pct
- Deals and private raises49th pct
- Patent publications22nd pct
Confident ↔ Hedging
Confident
- Call sentiment93rd pct
- Call confidence93rd pct
- Guidance changes93rd pct
- Risk factors added84th pct
- Insider open-market trades44th pct
- + Call sentiment
- + Guidance changes
- + Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver75th pct
- Stress filings48th pct
Credit
How these are built →Quest Diagnostics's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$5.6B
- Due within a year $0.0B
- Longer term $5.6B
- Default point $2.8B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
$0.5B
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Apr 27, 2026 | $500M | 5.000% | 2036 (10y) | +82bp | 5.158% |
| Aug 15, 2024 | $400M | 4.600% | 2027 (3y) | +70bp | 4.609% |
| Aug 15, 2024 | $600M | 4.625% | 2029 (5y) | +85bp | 4.649% |
| Aug 15, 2024 | $850M | 5.000% | 2034 (10y) | +113bp | 5.050% |
| Oct 30, 2023 | $750M | 6.400% | 2033 (10y) | +153bp | 6.406% |
From the pricing term sheets Quest Diagnostics filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Quest Diagnostics, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralQuest Diagnostics (DGX) Highlights Haystack MRD Test Accuracy in Colorectal Cancer Trials
gurufocus.com · via Marketaux · Oct 1, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (FEDERAL STREET STRATEGIES, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (QUEST DIAGNOSTICS INCORPORATED)third_quarter 2026 · $0.3 million
- Oct 20, 2026LobbyingLobbying report (TARPLIN, DOWNS & YOUNG, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (RED+BLUE STRATEGIES)third_quarter 2026 · $0.1 million
- Oct 6, 20268-KDirector or officer changeItem 5.02
- Aug 25, 2026Patent
- Aug 18, 2026Patent
- Aug 4, 2026PatentPatent granted: CANCER DIAGNOSIS USING KI-67US 12699095
- Aug 4, 2026Patent
- Jul 21, 2026LobbyingLobbying report (FEDERAL STREET STRATEGIES, LLC)second_quarter 2026 · $0.1 million
- Jul 21, 2026Patent
- Jul 20, 2026LobbyingLobbying report (QUEST DIAGNOSTICS INCORPORATED)second_quarter 2026 · $0.5 million
- Jul 17, 2026LobbyingLobbying report (RED+BLUE STRATEGIES)second_quarter 2026 · $0.1 million
- Jul 16, 2026LobbyingLobbying report (TARPLIN, DOWNS & YOUNG, LLC)second_quarter 2026 · $0.1 million
- May 21, 20268-KShareholder vote resultsItem 5.07
- May 8, 20268-KMaterial agreement signedItem 1.01
- Mar 12, 20268-KDirector or officer changeItem 5.02
- Feb 26, 202610-KAnnual report (10-K)0 risk factors added, 0 removed
- Nov 28, 2025Risk event
- Oct 1, 2025Risk event
- May 30, 2025Risk event
- May 22, 20258-KShareholder vote resultsItem 5.07
- Apr 17, 2025Risk event
- Feb 20, 202510-KAnnual report (10-K)1 risk factors added, 0 removed
- Feb 22, 202410-KAnnual report (10-K)1 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| DaVita DVA | $14.0B | $1.6B | Jun 30, 2026 |
| Labcorp LH | $14.3B | $1.2B | Jun 30, 2026 |
| Chemed Corporation CHE | $2.6B | $0.3B | Jun 30, 2026 |
| Cigna CI | $282B | — | Jun 30, 2026 |
| CVS Health CVS | $415B | $11.8B | Jun 30, 2026 |
| Baxter International BAX | $11.5B | — | Jun 30, 2026 |
| Intuitive Surgical ISRG | $11.0B | $3.2B | Jun 30, 2026 |
| Vertex Pharmaceuticals VRTX | $12.6B | $3.8B | Jun 30, 2026 |